# A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

> **NCT01351415** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 485 (actual)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Docetaxel
- **DRUG:** Erlotinib
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT01351415
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-25
- **Primary completion:** 2016-06-25
- **Final completion:** 2016-06-25
- **Target enrollment:** 485 (ACTUAL)
- **Last updated:** 2017-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01351415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01351415, "A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01351415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*